info:eu-repo/semantics/article
Novel hybrid lipid nanocapsules loaded with a therapeutic monoclonal antibody – Bevacizumab – and Triamcinolone acetonide for combined therapy in neovascular ocular pathologies
Fecha
2021-02Registro en:
Formica, María Lina; Legeay, Samuel; Bejaud, Jérôme; Montich, Guillermo Gabriel; Ullio Gamboa, Gabriela Veronica; et al.; Novel hybrid lipid nanocapsules loaded with a therapeutic monoclonal antibody – Bevacizumab – and Triamcinolone acetonide for combined therapy in neovascular ocular pathologies; Elsevier Science; Materials Science and Engineering: C; 119; 2-2021; 1-10
0928-4931
CONICET Digital
CONICET
Autor
Formica, María Lina
Legeay, Samuel
Bejaud, Jérôme
Montich, Guillermo Gabriel
Ullio Gamboa, Gabriela Veronica
Benoit, Jean-Pierre
Palma, Santiago Daniel
Resumen
The aim of this study was to design and develop a novel hybrid formulation based on lipid nanocapsules containing bevacizumab (BVZ), an effective therapeutic antibody, on the surface and triamcinolone acetonide (TA) in the inner core (BVZ-TA-LNC) intended to improve ocular therapy. Hence, a phase inversion-insertion one step method was developed to drug loading and surface modification of lipid nanocapsules by post-insertion of a bifunctional polymer, followed by antibody coupling using “click” chemistry. The covalent bond and antibody capacity binding to its specific antigen were confirmed by thermal analysis and immunoassay, respectively. BVZ-TA-LNC presented nanometric size (102 nm), negative surface potential (−19 mV) and exhibiting 56% of TA in the lipid core. BVZ-TA-LNC tended to prevent the endothelial cell migration and significantly prevented the capillary formation induced by the vascular endothelium growth factor (VEGF). The novel hybrid system allowed the co-loading of two different therapeutic molecules and may be promising to improve the therapy of eye disorders that occur with inflammation and/or neovascularization.